JPH09220281A - Sterilizing method for body fluid treating device and sterilized body fluid treating device - Google Patents

Sterilizing method for body fluid treating device and sterilized body fluid treating device

Info

Publication number
JPH09220281A
JPH09220281A JP8354601A JP35460196A JPH09220281A JP H09220281 A JPH09220281 A JP H09220281A JP 8354601 A JP8354601 A JP 8354601A JP 35460196 A JP35460196 A JP 35460196A JP H09220281 A JPH09220281 A JP H09220281A
Authority
JP
Japan
Prior art keywords
body fluid
sodium
sterilization
treatment device
treating device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP8354601A
Other languages
Japanese (ja)
Other versions
JP2754203B2 (en
Inventor
Toru Kuroda
徹 黒田
Hajime Yabushita
肇 藪下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Medical Co Ltd
Original Assignee
Asahi Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18438666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH09220281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Medical Co Ltd filed Critical Asahi Medical Co Ltd
Priority to JP8354601A priority Critical patent/JP2754203B2/en
Publication of JPH09220281A publication Critical patent/JPH09220281A/en
Application granted granted Critical
Publication of JP2754203B2 publication Critical patent/JP2754203B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To drastically reduce the damage to a body fluid treating device by sterilization while maintaining the effect of sterilization at the time of subjecting the body fluid treating device to radiation sterilization and to provide the body fluid treating device which is safe and useful for the living body sterilized by this sterilization method. SOLUTION: This sterilization method comprises subjecting the body fluid treating device to radiation sterilization in the state of impregnating the device with at least one kind of antioxidant soln. selected from sodium pyrrophosphite, sodium phosphite, sodium hydrogensulfite, acetone sodium bisulfite, sodium formadehyde sulfoxylate, sodium hydrosulfite and 1-ascorbic acid.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、血液、血漿、リン
パ液等の体液を処理し、その組成比を変化させたり、構
造物の機能を変化させたりする為に用いられる体液処理
装置及びその滅菌方法に関する。近年、医学、工学等の
科学技術の進歩により、各種疾患により変化してしまっ
た体液成分を正常な状態に戻すための体液処理装置、生
体の免疫能を変化させる為の体液処理装置等、種々の体
液処理装置が開発され、様々な疾患で治療効果を上げつ
つある。例えば、腎不全患者の血液成分を正常に戻す為
の人工腎臓、血液中に酸素を送り込む為の人工肺、癌、
肝硬変などが原因で貯留した腹水中のアルブミンの様な
有用成分を血液中に戻してやる為の腹水処理装置、膠原
病、自己免疫疾患等に用いられ血液中の自己抗体、免疫
複合体等の悪性物質を含む血漿を濾過するための血球/
血漿分離器、血漿中の悪性物質を含む高分子量物質だけ
を濾過する事により除去する為の濾過フィルター、血漿
中の悪性物質だけを選択的に吸着する吸着器、薬物中毒
患者の血液中から中毒惹起物質を吸着する為の吸着器、
肝臓病患者の血液中に増加するビリルビンを吸着する吸
着器、血液型不適合妊娠患者血液中の血液型物質を吸着
する吸着材、自己免疫疾患患者血液中の白血球、リンパ
球を除去する為の血球分離フィルター、白血病患者血液
中から白血病細胞を除去する為の血球分離フィルター、
血液中の免疫担当細胞を刺激し、特定の機能を誘導する
為の細胞刺激装置等を体液処理装置の例としてあげる事
ができる。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a body fluid treatment device used for treating body fluids such as blood, plasma, and lymph fluid, changing the composition ratio thereof, and changing the function of structures, and sterilization thereof. Regarding the method. In recent years, due to advances in science and technology such as medicine and engineering, various types of body fluid treatment devices, such as body fluid treatment devices for returning body fluid components that have changed due to various diseases to a normal state, and body fluid treatment devices for altering the immunity of living organisms, etc. Has been developed and is improving the therapeutic effect on various diseases. For example, an artificial kidney for returning blood components of renal failure patients to normal, an artificial lung for sending oxygen into the blood, cancer,
Ascites treatment equipment for returning useful components such as albumin in ascites fluid stored due to cirrhosis to blood, used for collagen diseases, autoimmune diseases, etc.Malignant such as autoantibodies and immune complexes in blood Blood cells for filtering plasma containing substances /
Plasma separator, filtration filter for removing only high molecular weight substances including malignant substances in plasma by filtration, adsorber for selectively adsorbing only malignant substances in plasma, poisoning from the blood of drug-poisoned patients Adsorber for adsorbing the inducer,
An adsorber that adsorbs bilirubin, which increases in the blood of patients with liver disease, an adsorbent that adsorbs blood group substances in the blood of incompatible blood type pregnant patients, and blood cells that remove leukocytes and lymphocytes from the blood of patients with autoimmune diseases Separation filter, blood cell separation filter for removing leukemia cells from leukemia patient blood,
A cell stimulating device or the like for stimulating immunocompetent cells in blood to induce a specific function can be given as an example of the body fluid treatment device.

【0002】[0002]

【従来の技術】体液処理装置で処理した体液は、通常、
生体に再輸注される事が多く、また、体液処理中に体液
の変性を防ぐ為にも、体液処理装置は滅菌して用いられ
るのが普通である。滅菌法には、加熱法(火炎法、乾熱
法、高圧蒸気法、流通蒸気法、煮沸法、間けつ法)、濾
過法、照射法(放射線法、紫外線法、高周波法)、ガス
法、薬液法等がある(日本薬局方、第11改正、一般試
験法(7)滅菌法及び無菌操作法)が、体液処理装置の
滅菌には通常高圧蒸気滅菌法、放射線(ガンマ線)滅菌
法、ガス(エチレンオキシド)法等が用いられる事が多
い。しかしながら、滅菌とは物質中の全ての微生物を殺
滅または除去する事を意味しているので、滅菌する事に
より、体液処理装置自体が多大な損傷を受ける事は容易
に考えられる事である。事実、特に、放射線滅菌法によ
って体液処理装置が受ける損傷は大きく、体液処理装置
構成素材の分解、着色等が起こり、体液を処理する際に
体液処理装置から体液側に低分子物質が溶出してしまう
という問題が起こって来る。特に、放射線に対して不安
定な蛋白質、ペプチド、アミノ酸等を構成素材としてい
る体液処理装置(例えば担体に蛋白質、ペプチド、アミ
ノ酸等を固定した吸着材、細胞刺激材等)、放射線によ
り変性し易いポリマーを用いた体液処理装置等では問題
であった。
Body fluids treated with a body fluid treatment device are usually
The body fluid treatment device is usually sterilized and used to prevent denaturation of the body fluid during the treatment of the body fluid in many cases. Sterilization methods include heating methods (flame method, dry heat method, high-pressure steam method, circulating steam method, boiling method, intercalation method), filtration method, irradiation method (radiation method, ultraviolet ray method, high-frequency method), gas method, There are chemical liquid methods (Japanese Pharmacopoeia, 11th revision, general test method (7) sterilization method and aseptic operation method), but for sterilization of body fluid treatment device, usually high pressure steam sterilization method, radiation (gamma ray) sterilization method, gas (Ethylene oxide) method is often used. However, since sterilization means killing or removing all microorganisms in a substance, it is easily conceivable that the sterilization of the body fluid treatment apparatus itself would cause great damage. In fact, particularly, the body fluid treatment device is greatly damaged by the radiation sterilization method, and the constituent materials of the body fluid treatment device are decomposed, colored, etc., and when the body fluid is processed, the low-molecular substances elute from the body fluid treatment device to the body fluid side. The problem of getting lost comes up. In particular, a body fluid treatment device (for example, an adsorbent in which a protein, peptide, amino acid, or the like is immobilized on a carrier, a cell stimulating material, or the like) using radiation-unstable proteins, peptides, amino acids, or the like as a constituent material, is easily modified by radiation. There was a problem with a body fluid treatment device or the like using a polymer.

【0003】[0003]

【発明が解決しようとする課題】本発明の目的は、上記
問題点に鑑み、体液処理装置を放射線滅菌するに当り、
滅菌効果は維持したまま滅菌による体液処理装置の損傷
を大幅に低減する放射線滅菌方法を提供する事にあり、
また、この滅菌方法により滅菌された生体にとって安全
かつ有用な体液処理装置を提供する事にある。
In view of the above problems, an object of the present invention is to sterilize a body fluid treatment device by radiation.
In providing a radiation sterilization method that greatly reduces damage to the body fluid treatment device due to sterilization while maintaining the sterilization effect,
Another object of the present invention is to provide a body fluid treatment device that is sterilized by this sterilization method and is safe and useful for living bodies.

【0004】[0004]

【課題を解決するための手段】本発明者らは上記目的に
沿って鋭意研究を重ねた結果、体液処理装置にある特定
の抗酸化剤溶液を含浸させた状態で放射線滅菌する事に
よって、体液処理装置の損傷を大幅に低減する事が可能
である事を見出し、更には、この滅菌法で滅菌した体液
処理装置が生体にとって安全かつ有用である事を確認
し、本発明をなすに到った。すなわち本発明は、体液処
理装置にピロ亜硫酸ナトリウム、亜硫酸ナトリウム、亜
硫酸水素ナトリウム、アセトンソジウムバイサルファイ
ト、ソジウムホルムアルデヒドスルホキシレート、ソジ
ウムハイドロサルファイト、l−アスコルビン酸の中か
ら選択される少なくとも1種類の抗酸化剤溶液を含浸さ
せた状態で放射線滅菌することを特徴とする体液処理装
置の滅菌方法であり、ピロ亜硫酸ナトリウム、亜硫酸ナ
トリウム、亜硫酸水素ナトリウム、アセトンソジウムバ
イサルファイト、ソジウムホルムアルデヒドスルホキシ
レート、ソジウムハイドロサルファイト、l−アスコル
ビン酸の中から選択される少なくとも1種類の抗酸化剤
溶液を含浸させた状態で放射線滅菌された体液処理装置
である。
Means for Solving the Problems The inventors of the present invention have conducted extensive studies in accordance with the above-mentioned object, and as a result, by carrying out radiation sterilization while impregnating a specific antioxidant solution in a body fluid treatment device, the body fluid It was found that it is possible to significantly reduce the damage to the treatment device, and further, it was confirmed that the body fluid treatment device sterilized by this sterilization method is safe and useful for the living body, and the present invention was completed. It was That is, in the present invention, the body fluid treatment device is selected from at least sodium pyrosulfite, sodium sulfite, sodium hydrogen sulfite, acetone sodium bisulfite, sodium formaldehyde sulfoxylate, sodium hydrosulfite, and 1-ascorbic acid. A method for sterilizing a body fluid treatment device, which comprises sterilizing radiation in a state of being impregnated with one type of antioxidant solution, which is sodium pyrosulfite, sodium sulfite, sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde. The body fluid treatment device is radiation-sterilized in a state of being impregnated with at least one antioxidant solution selected from sulfoxylate, sodium hydrosulfite, and 1-ascorbic acid.

【0005】[0005]

【発明の実施の形態】ここでいう体液処理装置とは、血
液、血漿、リンパ液、骨髄液等の体液を材料として、こ
の体液の電解質、ホルモン、蛋白質等の組成を変化させ
たり、赤血球、白血球、血小板あるいは白血球中の単
球、顆粒球、リンパ球さらにはリンパ球サブセットの組
成を変化させたり、その組成は変化させないまでも一部
のリンパ球を刺激してヘルパー機能、サプレッサー機
能、キラー機能等を誘導したりする為の処理装置であ
り、体液に対して何らかの変化を起こさせる装置であ
る。体液に対して何らかの変化を起こさせるための機構
としては、物理的な機構、化学的機構等種々あるが、例
えば透析、濾過、吸着、粘着、抗原抗体反応、比重差利
用、塩析、物理的刺激等様々なものが利用できる。体液
処理装置の例をここでもう一度例示すると、腎不全患者
の血液成分を正常に戻す為の人工腎臓、血液中に酸素を
供給する為の人工肺、腹水中のアルブミンを濃縮して再
静注する為の腹水処理装置、血液中の血球成分と血漿成
分とを分離する為の血漿濾過フィルター、血球を成分毎
に分離する為の遠心分離装置や血球分離フィルター、体
液中の特定成分を選択吸着する為の吸着器、血漿中の成
分を分子量によって分画する為の分画フィルター、特定
の血球を選択的に除去する為のフィルター、血液中の免
疫担当細胞を刺激して特定の機能を誘導する為の刺激装
置などがあり、ここに例示されていない物でも体液に対
して何らかの変化を起こさせる処理装置は全て含まれ
る。本発明で言う滅菌とは物質中のすべての微生物を殺
滅または除去することをいう。また本発明で言う抗酸化
剤とは、他の分子などに電子を与え易い性質を持つ原
子、分子あるいはイオンの事を言うが、体液処理装置が
酸素により変化を受けるのを抑制する性質を持つもので
ある。本発明で言う抗酸化剤は以下の7種類の中から選
択される。即ち、ピロ亜硫酸ナトリウム、亜硫酸水素ナ
トリウム、亜硫酸ナトリウム、アセトン−ソジウム−バ
イサルファイト、ソジウム−ホルムアルデヒド−スルホ
キシレート、ソジウムハイドロサルファイト、l−アス
コルビン酸である。これらの抗酸化剤は単独で用いても
良いし、2種類以上混合して用いても良い。以上例示し
た中では、ピロ亜硫酸ナトリウム、アセトンソジウムバ
イサルファイト、ソジウムホルムアルデヒドスルホキシ
レート、ソジウムハイドロサルファイト、l−アスコル
ビン酸が毒性、取り扱い性などの点から好んで用いら
れ、特にピロ亜硫酸ナトリウムが好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION The body fluid treatment device referred to here is a body fluid such as blood, plasma, lymph fluid or bone marrow fluid which is used to change the composition of electrolytes, hormones, proteins, etc. of this body fluid, and red blood cells and white blood cells. Changes the composition of monocytes, granulocytes, lymphocytes and lymphocyte subsets in platelets or leukocytes, or stimulates some lymphocytes, even if the composition does not change, to helper function, suppressor function, killer function It is a processing device for inducing the like, and is a device for causing some change in body fluid. There are various mechanisms for causing a certain change to the body fluid, such as a physical mechanism and a chemical mechanism. For example, dialysis, filtration, adsorption, adhesion, antigen-antibody reaction, utilization of specific gravity difference, salting out, physical Various things such as stimulation can be used. Here is another example of a body fluid treatment device. An artificial kidney for returning the blood components of a patient with renal failure to normal, an artificial lung for supplying oxygen to the blood, and albumin in ascites concentrated and re-injected Ascites treatment device, plasma filtration filter for separating blood cell components and plasma components in blood, centrifugal separator and blood cell separation filter for separating blood cells for each component, selective adsorption of specific components in body fluids Adsorber, a filter for fractionating components in plasma by molecular weight, a filter for selectively removing specific blood cells, stimulating immunocompetent cells in blood to induce specific functions There is a stimulating device for performing the above, and all the processing devices that cause some change to the body fluid are included in those which are not exemplified here. Sterilization in the present invention refers to killing or removing all microorganisms in a substance. In addition, the antioxidant referred to in the present invention refers to an atom, molecule or ion having a property of easily giving an electron to another molecule or the like, but having a property of inhibiting a body fluid treatment device from being changed by oxygen. Things. The antioxidant referred to in the present invention is selected from the following seven types. That is, sodium pyrosulfite, sodium bisulfite, sodium sulfite, acetone-sodium-bisulfite, sodium-formaldehyde-sulfoxylate, sodium hydrosulfite, and 1-ascorbic acid. These antioxidants may be used alone or as a mixture of two or more. Among the above examples, sodium pyrosulfite, sodium acetone bisulfite, sodium formaldehyde sulfoxylate, sodium hydrosulfite, l-ascorbic acid are preferably used in terms of toxicity, handleability, etc. Sodium is preferred.

【0006】体液処理装置に抗酸化剤溶液を含浸させる
方法は、抗酸化剤を適当な溶媒に溶解して体液処理装置
と接触させる方法、例えば、水または生理的塩溶液に抗
酸化剤を溶解させて体液処理装置に充填または含浸させ
る方法、グリセリン、アルコール等の溶剤に抗酸化剤を
溶かして体液処理装置に充填または含浸させる方法等が
用いられる。体液処理装置に抗酸化剤溶液が含浸し、酸
素により体液処理装置が変化を受けるのを抑制できる状
態になっている事が必要である。溶液状態にして抗酸化
剤を用いる場合、抗酸化剤の濃度は、体液処理装置の材
質、抗酸化剤の種類および滅菌の条件によって最適な濃
度が決定されるべきであるが、大体好ましくは0.00
1%から1%、より好ましいのは0.005%から0.
5%の濃度である。本発明で用いられる滅菌方法は、照
射法であるが、特に照射法のうちガンマ線法が好んで用
いられる。以下、本発明を実施する態様について、中空
糸型人工腎臓をガンマ線滅菌するケースを例にとって、
詳細に説明する。ガンマ線滅菌の場合、通常1〜5Mr
adのガンマ線を中空糸型人工腎臓に照射するのが一般
的であるが、この時、主に中空糸が劣化し、低分子物質
を生成することがある。この様な低分子物質は、この中
空糸型人工腎臓で体液を処理した場合に体液側に溶離し
てしまう可能性が否定できず問題となって来る。この問
題を解決する為に成された本発明によれば、例えば、上
記中空糸型人工腎臓の容器内に特定の抗酸化剤を溶解せ
しめた液体を充填しておくので、ガンマ線を照射しても
中空糸の劣化が防げ、低分子物質の生成が大幅に抑制さ
れる。これは、特定の抗酸化剤溶液を含浸させた事によ
り、中空糸素材の酸化劣化が防止され、低分子物質の生
成が抑制された事によると考えられる。特定の抗酸化剤
溶液を中空糸型人工腎臓に含浸させる方法は、上記方法
に限らず抗酸化剤をグリセリンの様な溶液に溶解せしめ
て中空繊維に含浸させる方法なども用いる事ができる。
中空糸の材質は、セルロースアセテート、セルロース、
ポリアクリロニトリル、メチルメタクリレート、ポリス
ルホン、脱酢酸セルロース、エチレンビニルアルコール
等各種あるが、程度の差こそあれ、ガンマ線滅菌による
劣化、低分子量物質の生成があり、これを抑制するため
に特定の抗酸化剤溶液を含浸させる事は非常に有用であ
る。また、抗酸化剤溶液を含浸させる事により、容器表
面の劣化、中空糸を結束接着する為の接着材等の劣化も
防ぐ事ができ非常に有効である。
A method of impregnating a body fluid treatment device with an antioxidant solution is a method of dissolving an antioxidant in an appropriate solvent and contacting the body fluid treatment device, for example, dissolving the antioxidant in water or a physiological salt solution. And a method of dissolving an antioxidant in a solvent such as glycerin or alcohol and filling or impregnating the body fluid treatment device. It is necessary that the body fluid treatment device is impregnated with the antioxidant solution so that the body fluid treatment device can be prevented from being changed by oxygen. When the antioxidant is used in the form of a solution, the optimal concentration of the antioxidant should be determined by the material of the body fluid treatment device, the type of the antioxidant, and the sterilization conditions. .00
1% to 1%, more preferably 0.005% to 0.1%.
It is a concentration of 5%. The sterilization method used in the present invention is an irradiation method, and a gamma ray method is particularly preferred among the irradiation methods. Hereinafter, with respect to an embodiment of the present invention, taking a case of gamma ray sterilization of a hollow fiber type artificial kidney as an example,
This will be described in detail. In the case of gamma ray sterilization, usually 1 to 5 Mr
Generally, gamma rays of ad are irradiated to the hollow fiber type artificial kidney. At this time, the hollow fiber mainly deteriorates, and a low molecular substance may be generated. Such a low molecular weight substance poses a problem since the possibility of elution toward the body fluid when the body fluid is treated with the hollow fiber type artificial kidney cannot be denied. According to the present invention made in order to solve this problem, for example, since a liquid in which a specific antioxidant is dissolved is filled in the container of the hollow fiber type artificial kidney, gamma rays are irradiated. Also, the deterioration of the hollow fiber can be prevented, and the generation of low molecular substances can be greatly suppressed. This is probably because the impregnation with the specific antioxidant solution prevented the oxidative deterioration of the hollow fiber material and suppressed the generation of low molecular substances. The method of impregnating the hollow fiber artificial kidney with the specific antioxidant solution is not limited to the above method, and a method of dissolving the antioxidant in a solution such as glycerin and impregnating the hollow fibers can be used.
The material of the hollow fiber is cellulose acetate, cellulose,
There are various types such as polyacrylonitrile, methyl methacrylate, polysulfone, cellulose deacetate, ethylene vinyl alcohol, etc.Depending on the degree, there is degradation due to gamma ray sterilization, generation of low molecular weight substances, and specific antioxidants to suppress this Impregnating the solution is very useful. Impregnation with an antioxidant solution is also very effective because it can prevent deterioration of the surface of the container and deterioration of an adhesive or the like for binding and bonding hollow fibers.

【0007】[0007]

【実施例】以下、本発明の実施例を比較例と共に示す
が、本発明はこれに限定されるものではない。
EXAMPLES Examples of the present invention will be shown below together with comparative examples, but the present invention is not limited thereto.

【0008】[0008]

【実施例1】キュプラアンモニウムレーヨン中空糸(内
径200μm、膜厚11μm)7300本の両末端をポ
リウレタン樹脂でポッティングし、円筒状の外筒に内蔵
して人工腎臓を組立てた後、血液側と透析液側を各々1
500mlのピロ亜硫酸ナトリウム水溶液で洗浄充填し
た。水溶液中のピロ亜硫酸ナトリウム水溶液の濃度は、
0.01g/dl、0.1g/dl、0.5g/dlの
3水準とした。この後、人工腎臓をポリエチレン製の袋
に封入し、ダンボールケースに入れて包装し、この状態
でガンマー線2.5Mradを照射して滅菌処理した。
滅菌処理後の充填液を試験液として測定を行なった。
Example 1 7300 cupra ammonium rayon hollow fibers (internal diameter 200 μm, film thickness 11 μm) were potted at both ends with a polyurethane resin, built into a cylindrical outer cylinder to assemble an artificial kidney, and then dialyzed with the blood side. Liquid side 1 each
Wash and fill with 500 ml of aqueous sodium pyrosulfite solution. The concentration of the sodium pyrosulfite aqueous solution in the aqueous solution is
Three levels of 0.01 g / dl, 0.1 g / dl and 0.5 g / dl were set. Thereafter, the artificial kidney was sealed in a polyethylene bag, packed in a cardboard case, and sterilized by irradiating 2.5 Mrad of gamma rays in this state.
Measurement was performed using the filling liquid after the sterilization treatment as a test liquid.

【0009】[0009]

【比較例1】キュプラアンモニウムレーヨン中空糸型人
工腎臓を組立てた後、純水を用いて実施例1と同様に操
作し2.5Mradのガンマー線滅菌処理を行ない、充
填液を試験液として測定を行なった。上記の試験液につ
いて紫外部の吸光度および可視部の吸光度を測定した。
紫外部の吸光度の測定方法は、10mmの測定セルを用
い、測定波長220nmから350nmの間で吸収が最
も強く出る点の吸光度を求めた。吸光度を測定する時の
比較液にはそれぞれの濃度の充填水を使用した。また、
可視部の吸光度の測定は溶液の黄変度を測定する目的で
波長420nmで行なった。測定結果を表1に示す。 全てのデータにおいて、ピロ亜硫酸ナトリウムを用いた
ものが比較例1(抗酸化剤を用いなかった場合)と比べ
て、溶出している物質の量が少なく、また溶液の黄変度
合も少ないことがわかる。
[Comparative Example 1] A cupra ammonium rayon hollow fiber type artificial kidney was assembled, and then 2.5 Mrad gamma ray sterilization treatment was performed in the same manner as in Example 1 using pure water, and the filling liquid was used as a test liquid for measurement. I did. The UV absorbance and the visible absorbance of the above test solution were measured.
As a method of measuring the absorbance of ultraviolet light, a 10-mm measurement cell was used, and the absorbance at the point where the absorption was highest between the measurement wavelengths of 220 nm and 350 nm was determined. Filling water of each concentration was used as a comparison solution when measuring the absorbance. Also,
The absorbance in the visible part was measured at a wavelength of 420 nm for the purpose of measuring the yellowing degree of the solution. Table 1 shows the measurement results. In all the data, the results using sodium pyrosulfite showed that the amount of eluted substances was smaller and the degree of yellowing of the solution was lower than that of Comparative Example 1 (when no antioxidant was used). Recognize.

【0010】[0010]

【実施例2】実施例1と同じ人工腎臓を用い、抗酸化剤
として、亜硫酸水素ナトリウム(0.01g/dl)、
アセトンソジウムバイサルフアイト(0.1g/d
l)、ソジウムホルムアルデヒドスルホキシレート
(0.1g/dl)の各水溶液を使用した以外は全て実
施例1と同様の実験を行なった。結果を表2に示す。抗
酸化剤ナシのデータは比較例1のデータを用いた。ガン
マー線の照射線量は2.5Mradとした。 全ての抗酸化剤について溶出物質の量が少なくなり、溶
液の黄変度合も改善されていることがわかる。
Example 2 Using the same artificial kidney as in Example 1, sodium bisulfite (0.01 g / dl) was used as an antioxidant.
Acetone sodium bisulfite (0.1 g / d
l) The same experiment as in Example 1 was performed except that each aqueous solution of sodium formaldehyde sulfoxylate (0.1 g / dl) was used. Table 2 shows the results. As the data of the antioxidant pear, the data of Comparative Example 1 was used. The irradiation dose of gamma rays was 2.5 Mrad. It can be seen that the amount of eluted substances was reduced for all antioxidants and the degree of yellowing of the solution was also improved.

【0011】[0011]

【実施例3】人工腎臓用セルロース中空糸(内径200
μm、膜厚11μm)をガラスビーカー中のピロ亜硫酸
ナトリウム水溶液(0.1g/dl)へ浸漬し、ポリエ
チレン製フィルムで包装し、この状態でガンマー線2.
5Mradを照射した。この後、中空糸を溶液中から取
り出し、中空糸の引張強度及び伸度の測定を行なった。
Example 3 Cellulose hollow fiber for artificial kidney (inner diameter 200
μm, film thickness of 11 μm) was immersed in an aqueous solution of sodium pyrosulfite (0.1 g / dl) in a glass beaker, packaged with a polyethylene film, and then gamma-rayed in this state.
Irradiated 5 Mrad. Thereafter, the hollow fiber was taken out of the solution, and the tensile strength and elongation of the hollow fiber were measured.

【0012】[0012]

【比較例2】セルロース中空糸(実施例3と同様)をガ
ラスビーカー中の蒸留水へ浸漬し、この状態で2.5M
radのガンマー線を照射して中空糸の引張強度及び伸
度の測定を行なった。測定結果を表3に示す。 抗酸化剤としてピロ亜硫酸ナトリウムを用いたものは、
抗酸化剤を用いなかったもの(比較例2)と比べて、引
張強度、伸度とも優れていた。
Comparative Example 2 Cellulose hollow fibers (same as in Example 3) were immersed in distilled water in a glass beaker, and in this state 2.5M.
By irradiating rad gamma rays, the tensile strength and elongation of the hollow fiber were measured. Table 3 shows the measurement results. Those using sodium pyrosulfite as an antioxidant,
Both the tensile strength and the elongation were superior to those without the antioxidant (Comparative Example 2).

【0013】[0013]

【発明の効果】以上述べた様に、体液処理装置に特定の
抗酸化剤溶液を含浸させた状態で放射線滅菌する事によ
り、従来起こっていた体液処理装置の構成材料の劣化、
劣化に伴なう低分子物質の生成等を大幅に少なくする事
が可能になり、本発明により放射線滅菌された体液処理
装置は生体にとって安全かつ有用な体液処理装置になっ
た。
As described above, by sterilizing radiation in a state where the body fluid treatment device is impregnated with a specific antioxidant solution, deterioration of the constituent materials of the body fluid treatment device, which has conventionally occurred,
It is possible to significantly reduce the generation of low molecular weight substances due to deterioration, and the radiation-sterilized body fluid treatment device according to the present invention has become a safe and useful body fluid treatment device for living organisms.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 体液処理装置にピロ亜硫酸ナトリウム、
亜硫酸ナトリウム、亜硫酸水素ナトリウム、アセトンソ
ジウムバイサルファイト、ソジウムホルムアルデヒドス
ルホキシレート、ソジウムハイドロサルファイト、l−
アスコルビン酸の中から選択される少なくとも1種類の
抗酸化剤溶液を含浸させた状態で放射線滅菌することを
特徴とする体液処理装置の滅菌方法。
1. A body fluid treatment device comprising sodium pyrosulfite,
Sodium sulfite, sodium hydrogen sulfite, acetone sodium bisulfite, sodium formaldehyde sulfoxylate, sodium hydrosulfite, l-
A method for sterilizing a body fluid treatment device, which comprises sterilizing radiation in a state of being impregnated with at least one antioxidant solution selected from ascorbic acid.
【請求項2】 ピロ亜硫酸ナトリウム、亜硫酸ナトリウ
ム、亜硫酸水素ナトリウム、アセトンソジウムバイサル
ファイト、ソジウムホルムアルデヒドスルホキシレー
ト、ソジウムハイドロサルファイト、l−アスコルビン
酸の中から選択される少なくとも1種類の抗酸化剤溶液
を含浸させた状態で放射線滅菌された体液処理装置。
2. At least one antibacterial agent selected from sodium pyrosulfite, sodium sulfite, sodium hydrogen sulfite, acetone sodium bisulfite, sodium formaldehyde sulfoxylate, sodium hydrosulfite, and 1-ascorbic acid. A body fluid treatment device that has been sterilized by radiation while being impregnated with an oxidant solution.
JP8354601A 1996-12-20 1996-12-20 Sterilization method for body fluid treatment device and sterilized body fluid treatment device Expired - Fee Related JP2754203B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8354601A JP2754203B2 (en) 1996-12-20 1996-12-20 Sterilization method for body fluid treatment device and sterilized body fluid treatment device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8354601A JP2754203B2 (en) 1996-12-20 1996-12-20 Sterilization method for body fluid treatment device and sterilized body fluid treatment device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP62040148A Division JP2649224B2 (en) 1987-02-25 1987-02-25 Sterilization method for body fluid treatment device and sterilized body fluid treatment device

Publications (2)

Publication Number Publication Date
JPH09220281A true JPH09220281A (en) 1997-08-26
JP2754203B2 JP2754203B2 (en) 1998-05-20

Family

ID=18438666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8354601A Expired - Fee Related JP2754203B2 (en) 1996-12-20 1996-12-20 Sterilization method for body fluid treatment device and sterilized body fluid treatment device

Country Status (1)

Country Link
JP (1) JP2754203B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006305333A (en) * 2005-03-29 2006-11-09 Asahi Kasei Medical Co Ltd Module for hemofiltration or hemodiafiltration

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104117A1 (en) 2005-03-29 2006-10-05 Toray Industries, Inc. Modified substrate and process for production thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6094438A (en) * 1983-10-26 1985-05-27 ベクトン・デイツキンソン・アンド・カンパニ− Stabilization of semi-crystalline polymer against high energy radiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6094438A (en) * 1983-10-26 1985-05-27 ベクトン・デイツキンソン・アンド・カンパニ− Stabilization of semi-crystalline polymer against high energy radiation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006305333A (en) * 2005-03-29 2006-11-09 Asahi Kasei Medical Co Ltd Module for hemofiltration or hemodiafiltration

Also Published As

Publication number Publication date
JP2754203B2 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
RU2475252C1 (en) Method for preparing high-temperature stable pharmaceutical composition containing oxygen carrier and using it
US8926543B2 (en) Immunoactivation blood perfusion filter for the treatment of malignant tumors
CA2334680A1 (en) Method of removing beta-2 microglobulin from blood
EP1621220B1 (en) Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment
CN102600521A (en) Device and method for eliminating pathogens in blood
JP2006291193A (en) Reformed substrate and manufacturing method thereof
JP5320941B2 (en) Method for producing membrane for biocomponent contact application
WO2019084111A1 (en) Apparatus and methods to remove toxins from blood by plasmaspheresis
JPH04187206A (en) Leucocyte separator and production of leucocyte separating material
JP2672051B2 (en) Method for manufacturing blood purification device
JP2754203B2 (en) Sterilization method for body fluid treatment device and sterilized body fluid treatment device
CN107649102B (en) Preparation method of composite hollow fiber adsorption resin
US8808977B2 (en) Method of inactivating virus in circular blood and its applications in treating viral diseases
JPH0260660A (en) Adsorbent for treating body fluid
JP4190456B2 (en) Irradiation sterilization method for cell adsorbent and cell sterilized cell adsorbent
JP4201313B2 (en) Toxic substance binding albumin removal system
JP2649224B2 (en) Sterilization method for body fluid treatment device and sterilized body fluid treatment device
JPS61109573A (en) Asceptic water filled serum separator and its production
JP2584261B2 (en) Hemoglobin adsorbent
JPH0611324B2 (en) Porous hollow fiber membrane
JPS5826819A (en) Porous glass adsorbent for low-density lipoprotein particles
JPWO2002083202A1 (en) Body fluid treatment adsorber
JPH09299477A (en) Cholesterol adsorptive material, cholesterol removing filter and method for removing cholesterol
JP2004321720A (en) Production method of hollow fiber membrane type module and hollow fiber membrane type module
ITTO950387A1 (en) DIALIZER / REACTOR FILTER TO CARRY OUT THE CAPTURE OF ENDOTOXINS, AND PROCEDURE FOR ITS REALIZATION.

Legal Events

Date Code Title Description
S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees